For several weeks, the Covid-19 headline has been the Delta Variant. Much discussion is focussed on the lasting vs. waning protection of the various vaccines. Today, 12 July 2021, Pfizer is set to speak with U.S. officials to try to convince them of the need for a booster shot. According to Pfizer and BioNTech, clinical studies could begin as early as August, subject to regulatory approvals.
The companies say that although they believe a third shot of the two-dose vaccine has the potential to retain the “highest levels” of protection against all currently known variants, including delta, they are “remaining vigilant” and developing an updated version of the vaccine.
“As seen in real world evidence released from the Israel Ministry of Health, vaccine efficacy has declined six months post-vaccination, at the same time that the Delta variant is becoming the dominate variant in the country,” the companies said in a written statement.
“These findings are consistent with an ongoing analysis from the companies’ Phase 3 study,” they said. “That is why we have said, and we continue to believe that it is likely, based on the totality of the data we have to date, that a third dose may be needed within 6 to 12 months after full vaccination.”
Meanwhile, fueled by the Delta Variant, many countries are entering what is being called the Third Wave. These countries and regions are particularly concerned due to their low vaccination rates.